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Abstract
Background: Venous thromboembolism (VTE) remains a common problem in critically ill patients. Pharmacologic
prophylaxis is currently the standard of care based on high-level evidence from randomized controlled trials.
However, limited evidence exists regarding the effectiveness of intermittent pneumatic compression (IPC) devices.
The Pneumatic compREssion for preventing VENous Thromboembolism (PREVENT trial) aims to determine whether
the adjunct use of IPC with pharmacologic prophylaxis compared to pharmacologic prophylaxis alone in critically ill
patients reduces the risk of VTE.
Methods/Design: The PREVENT trial is a multicenter randomized controlled trial, which will recruit 2000 critically ill
patients from over 20 hospitals in three countries. The primary outcome is the incidence of proximal lower
extremity deep vein thrombosis (DVT) within 28 days after randomization. Radiologists interpreting the scans are
blinded to intervention allocation, whereas the patients and caregivers are unblinded. The trial has 80 % power to
detect a 3 % absolute risk reduction in proximal DVT from 7 to 4 %.
Discussion: The first patient was enrolled in July 2014. As of May 2015, a total of 650 patients have been enrolled
from 13 centers in Saudi Arabia, Canada and Australia. The first interim analysis is anticipated in July 2016. We
expect to complete recruitment by 2018.
Trial registration: Clinicaltrials.gov: NCT02040103 (registered on 3 November 2013).
Current controlled trials: ISRCTN44653506 (registered on 30 October 2013).
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Background
Venous thromboembolism (VTE), including both deep
vein thrombosis (DVT) and pulmonary embolism (PE),
is a common complication of critical illness and is associ-
ated with increased morbidity and mortality [1]. Supported
by high-quality evidence, pharmacologic thromboprophy-
laxis is recommended for critically ill patients [2].
The evidence regarding the effectiveness of mechanical
prophylaxis including an intermittent pneumatic compres-
sion device (IPC) and graduated compression stockings
(GCS) for thromboprophylaxis is less clear. A systematic
review by Limpus et al. included two randomized con-
trolled trials that compared IPC to low-molecular-weight
heparin (LMWH) in critically ill trauma patients [3, 4] and
found no statistically significant difference in DVT rates
between IPC and LMWH (risk ratio 2.37, 95 % 0.57–9.90)
[5]. As such, clinical practice guidelines recommend that
IPC be reserved for patients with contraindications to
pharmacologic thromboprophylaxis [6]. In a cohort study
using a propensity score-adjusted analysis, we found that
incident VTE was lower with the use of IPC (versus no
IPC) but not GCS (versus no GCS) [7]. This association
of lower VTE with IPC was consistent regardless of the
use and type of prophylactic heparin (unfractionated or
LMWH), the type of admission (trauma or non-trauma,
surgical or non-surgical). These findings suggest that
IPC may provide thromboprophylaxis if used as an
alternative to unfractionated heparin (UFH) or LMWH,
and also when used as an adjunct to pharmacologic
thromboprophylaxis. The largest trial to date on the
effectiveness of IPC is the CLOTS 3 (Clots in Legs Or
sTockings after Stroke) trial, which randomized 2876
stroke patients in 94 UK centers to IPC versus no IPC;
the indication of pharmacologic prophylaxis was left to
the appreciation of the treating team. The primary out-
come was proximal vein DVT on screening ultrasound
or any symptomatic DVT in the proximal veins, con-
firmed on imaging, within 30 days of randomization.
The primary outcome occurred in 8.5 % of patients
allocated to IPC and in 12.1 % of patients allocated to
no IPC; with an absolute risk reduction of 3.6 % (95 %
CI 1.4–5.8) [8]. Of note, fewer than 25 % of patients in
CLOTS 3 received pharmacologic thromboprophylaxis.
Nevertheless, the protective effect of IPC was observed
whether pharmacologic thromboprophylaxis was or was
not given. Regarding GCS, two trials (CLOTS 1 and
CLOTS 2) documented a lack of effectiveness of GCS
in thromboprophylaxis in stroke patients [9, 10].
The thromboprophylactic effect of IPC is thought to be
related to enhancing venous blood flow in the lower ex-
tremities, increase in endogenous fibrinolysis, stimulation
of vascular endothelial cells and a reduction in venous
caliber [4]. In a study on normal volunteers the use of IPC
was associated with increased endogenous fibrinolysis;
tissue factor pathway inhibitor and plasminogen activator
activity both increased after applying pneumatic compres-
sion for 2 h [11]. The IPC may have several hemodynamic
effects; as it has been shown to augment venous return,
increase central venous pressure and pulmonary arterial
pressure [12] and increase cardiac output in healthy vol-
unteers [13]. While the clinical implications of the
hemodynamic effects of IPC remain unknown, one manu-
facturer (Tyco) lists cardiogenic pulmonary edema as a
contraindication for IPC. Cutaneous complications are a
concern with IPC; in CLOTS 3, lower extremity skin le-
sions were reported in 3 % of IPC patients versus 1 % of
control patients (p = 0.002) [8].
The lack of clear evidence for IPC and GCS has been
reflected in the wide variation in the use of these devices
in surveys from Canada, France, Australia and Germany
[5, 14–17], and more importantly, in the current practice
guidelines. The American College of Physicians (ACP)
guidelines for non-surgical patients recommend against
the use of GCS, and suggest IPC as an alternative to
pharmacologic thromboprophylaxis if the patient has a
contraindication; but make no recommendation about its
adjunct use to pharmacologic thromboprophylaxis [6].
In contrast, The American College of Chest Physicians’
(ACCP) 2012 guidelines recommend the use of GCS or
IPC, although preference is given to IPC as an alternative
but not as an adjunct to pharmacologic thromboprophy-
laxis in non-surgical critically ill patients [2].
Study objectives
The primary objective of the PREVENT trial is to assess
the superiority of adjunct use of IPC to pharmacologic
thromboprophylaxis compared to pharmacologic throm-
boprophylaxis alone on the incidence of proximal DVT
in critically ill patients.
Secondary objectives
1. To study the effect of adjunct use of IPC on the
incidence of pulmonary embolism and of distal
lower extremity DVT
2. To study the effect of the adjunct use of IPC on
intensive care unit (ICU), hospital and 90-day
mortality and hospital length of stay (LOS)
3. To study the effect of adjunct use of IPC on
hemodynamic status in terms of the need for
vasopressor therapy
4. To study the effect of adjunct use of IPC on patients
with heart failure in terms of ventilator-free days
5. To study the effect of adjunct use of IPC on
VTE in the following subgroups: trauma, patients
with central venous catheters in the femoral
veins, stroke, postoperative patients, heart failure
and shock
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6. To examine whether there are differences in the
effect of IPC based on whether UFH or LMWH
is used
7. To examine whether there are differences in the
thromboprophylactic effect between sequential and
non-sequential IPCs
8. To examine whether there are differences in
below-knee and above-knee sleeves
9. To examine whether IPC applied to the lower
extremities reduces non-lower extremity thrombosis
10.To examine if there is dose-effect relationship of the
IPC duration and incident DVT risk
11.To examine whether IPC increases the risk of skin
ulcers or lower extremity ischemia and affects
mobilization practice
Tertiary objective
To test whether there are differences among different
LMWHs (enoxaparin, dalteparin and others) in VTE
prophylaxis compared to UFH.
Methods/Design
Design overview
The PREVENT trial is an international multicenter trial ap-
proved by the Institutional Review Board (IRB) of the Min-
istry of National Guard Health Affairs (MNGHA) in which
eligible patients will be randomized to IPC or no IPC. The
trial is registered in ClinicalTrials.gov: NCT02040103 and
Current controlled trials: ISRCTN44653506. The study is
sponsored by King Abdulaziz City for Science and Technol-
ogy (AT 65 – 34) and King Abdullah International Medical
Research Center (RC12/045/R), Riyadh, Saudi Arabia.
Eligibility and enrollment
All patients admitted to the ICU will be screened for
eligibility within the first 48 h of ICU admission. To
enter the study, patients must fulfill the inclusion criteria
and meet no exclusion criteria as detailed in Table 1.
Eligible patients or their substitute decision-maker will be
approached for written informed consent. No compensa-
tion is provided for enrollment in the trial.
Informed consent
The study is conducted according to Good Clinical Prac-
tice guidelines. The study protocol as well as the informed
consent have been approved by the IRB of King Abdullah
International Medical Research Center, King Abdulaziz
Medical City, Riyadh and the respective IRBs of all the
other centers.
The research coordinator and/or physician investigator
explains the objectives of the trial, and its potential risks
and benefits, to the patient when possible or more com-
monly to his/her surrogate decision-maker. A witnessed
written consent is obtained thereafter. The patient or
surrogate decision-maker can withdraw from the study at
any time without penalty or impact on patient care. A rec-
ord is kept of all the patients who meet the inclusion cri-
teria but are not randomized or withdrawn from the
study.
Trial interventions
The intervention group will receive IPC in addition to
pharmacologic prophylaxis ordered by the treating team;
the control group will receive pharmacologic prophylaxis
only. All IPC devices intended for DVT prophylaxis can
be used in the study. Sequential devices (with multi-
chamber cuffs) are preferred, but non-sequential (with
single-chamber cuffs) are acceptable. The type of device
will be documented.
The use of IPC will follow the manufacturer’s instruc-
tions and local policies. IPC will be applied to both legs.
We will use preferably thigh-length sleeves, but knee-
length sleeves are acceptable. Foot pumps may be used in
addition to the thigh- or knee-length sleeves. The ability
to use IPC on both legs is one of the inclusion criteria.
However, if during the study period the IPC could not be
used on one leg, it should be continued on the other side
and the use of a foot pump on the contraindicated leg
considered if available. We aim to apply IPC continuously,
Table 1 Study inclusion and exclusion criteria
Inclusion criteria
• Medical-surgical ICU patients ≥14 years old at participating ICUs.
ICUs that use other age cut-off for adult patients will adhere to their
local standard (16 or 18 years)
• Patient weight ≥45 kg
• Expected ICU LOS ≥72 h
• Eligible for pharmacologic thromboprophylaxis with UFH and LMWH
Exclusion criteria
• Patient treated with IPC for >24 h in this current ICU admission
• Patient in the ICU for >48 h
• Patient treated with pharmacologic VTE prophylaxis with medications
other than UFH or LMWH
• Inability or contraindication to applying IPC to both legs:
○ Burns in the lower extremities, lacerations, active skin infection
and ischemic lower limb at the site of IPC placement
○ Acute ischemia in the lower extremities
○ Amputated foot or leg on one or both sides
○ Compartment syndrome
○ Severe peripheral arterial disease
○ Vein ligation, gangrene, recent vein grafts and draining incisions
○ Evidence of bone fracture in lower extremities
• Therapeutic dose of anticoagulation with UFH or LMWH
• Pregnancy
• Limitation of life support, life expectancy ≤7 days or palliative care
• Allergy to the sleeve material
• Patients with inferior vena cava (IVC) filter
Eligible non-randomized exclusion criteria
▪ Patient or substitute decision-maker declines consent
▪ Unable to obtain consent within 48 h of ICU admission
▪ ICU physician or other treating clinician declines consent
▪ Co-enrollment in trials with biologic interaction
ICU intensive care unit, IPC intermittent pneumatic compression, LMWH
low-molecular-weight heparin, LOS length of stay, UFH unfractionated
heparin, VTE venous thromboembolism
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both day and night for at least 18 h per day. The IPC may
be removed during washing, physiotherapy, or screening
compression duplex ultrasound. Nursing staff will record
the application of IPC on the patient chart or on a daily
data collection form designed to track adherence.
Stopping guidelines for the intervention
Table 2 outlines the stopping guidelines for the interven-
tion and the subsequent action. The intervention may be
stopped in the following situations:
1. Suspected or confirmed DVT: if there is suspicion of
DVT, the IPC should be stopped until ultrasound
excludes the diagnosis. If DVT is excluded, the IPC
should be re-started
2. Suspected or confirmed PE: if there is suspicion of
PE, the IPC should be stopped until the necessary
work-up, such as spiral computed tomography (CT)
scan, excludes the diagnosis. If PE is excluded, the
IPC should be resumed
3. Pressure ulcer or ischemia that prevents the use of IPC
4. Change in focus of care to palliation
5. Patient is discharged from the ICU or has been in
the trial for 28 days. At this point, the use of IPC is
at the discretion of the treating team
6. Patient becomes fully mobile and no longer requires
thromboprophylaxis in the judgment of their treating
team
Randomization
We will use a central, computer-based randomization
system with variable blocks to conceal allocation. We
will stratify based on center and pharmacologic throm-
boprophylaxis regimen (UFH or LMWH).
Duration of the intervention
The study interventions will continue for the duration of
the ICU stay or up to 28 days after randomization, after




We aim to blind the radiologist interpreting the scans
to detect DVTs and the study statistician. However,
because of the nature of the intervention, the treating
team and the ultrasonographer/technician performing
the venous leg ultrasound will not be blinded to the
intervention.
Minimizing contamination
Research coordinators will ensure enrollment of patients
as quickly as possible after ICU admission. We will cre-
ate a weekend on-call rota for the research coordinators
in as many centers as possible. Patients receiving early
IPC for more than 24 h will be excluded to eliminate
early contamination.
Table 2 Intervention stopping rules
Event Action regarding the intervention Action regarding other study procedures (data
collection, ultrasounds, 28- and 90-day outcomes)
Suspected DVT Hold intervention temporarily Continue other study procedures
Confirmed DVT Stop intervention permanently This is a predefined endpoint
Suspected PE Hold intervention temporarily Continue other study procedures
Confirmed PE Stop intervention permanently This is a predefined endpoint
Non-lower extremity thrombosis Continue intervention Continue other study procedures
Anticoagulation for reasons other than PE or DVT Continue intervention Continue other study procedures
Prophylactic IVC filter placement Continue intervention Continue other study procedures
Severe skin ulcerations due to IPC Hold intervention temporarily Continue other study procedures
Ischemia due to IPC Hold intervention temporarily Continue other study procedures
Intolerance of IPC Hold intervention temporarily Continue other study procedures
Withdrawal from the study Stop intervention permanently Ask for permission to continue, if not stop.
Pharmacologic thromboprophylaxis is withheld Apply IPC until pharmacologic prophylaxis
is resumed (in both groups)
Continue other study procedures
Physician requests IPC in the control group Place IPC and document the reason Continue other study procedures
IPC not placed by mistake in the IPC group or
placed by mistake in the control group
Resume the assigned intervention as
soon as possible, document the reason,
report as a violation
Continue other study procedures
Change in focus of care to palliation Stop intervention permanently. IPC may be
used at the discretion of the treating team
Stop ultrasounds. Continue other study procedures
DVT deep vein thrombosis, IPC intermittent pneumatic compression, IVC inferior vena cava, PE pulmonary embolus
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Co-interventions
The ICU team will have full, independent control of
patient management and as such, management other
than IPC will not be influenced by the allocated inter-
vention. The trial patients may have other risk factors
that may modify the risk for development of DVT.
Research coordinators will record all such risk factors.
These may include drugs such as antiplatelet agents
(aspirin, ticlopidine, clopidogrel) and anticoagulants that
are started after randomization (warfarin, therapeutic-dose
LMWH, therapeutic heparin administered intravenously,
other anticoagulants). The use of these medications will be
at the discretion of the clinical team. The use of GCS will
not be permitted; if used the reason will be documented.
Outcomes and follow-up
Primary outcome
The primary outcome is incident proximal lower extrem-
ity DVT detected after the third calendar day of enroll-
ment. Certified ultrasonographers will perform routine
twice weekly bilateral proximal lower extremity venous
ultrasound, and if DVT is clinically suspected. The first
ultrasound is performed within 48 h of enrollment. Preva-
lent DVT is defined as DVT documented within the first
three calendar days of enrollment, and is considered to re-
flect a baseline characteristic and less likely be related to
the study intervention. Patients with prevalent DVT will
be included in the main analysis but a prevalent throm-
bosis is not considered a primary outcome.
We focus on proximal DVTs because they are much
more reliably detected by ultrasound and are generally
regarded as clinically more important. We will use the
methodology used in the PROTECT trial to screen for
proximal lower extremity DVTs [18]. The venous system
will be examined at 1-cm intervals, documenting com-
pressibility at the following six sites: common femoral,
proximal superficial femoral, mid superficial femoral, distal
superficial femoral, popliteal veins and trifurcation. DVT in
any of these six sites qualifies as the primary outcome.
We will follow the same definitions used for VTE/DVT
in the PROTECT trial [18]. We define DVT if there is a
partially or completely incompressible venous segment.
Venous wall thickening is not considered diagnostic of
DVT. If a venous segment is not well visualized and is
never well visualized on subsequent ultrasounds, the test is
considered indeterminate; such events will be recorded but
are not considered trial outcomes. Ultrasonographers may
scan the distal leg veins at their discretion [18]. Distal
DVT will be documented as a secondary endpoint.
DVTs are considered chronic if a test prior to enroll-
ment reveals evidence of thrombus in the same or con-
tiguous venous segment. DVTs and other VTE events are
labeled as incident if they occur more than 3 calender days
after randomization. We define a thrombus as catheter-
related if a catheter had been in situ in the same or a con-
tiguous venous segment within 3 calender days of the
diagnosis. This definition is consistent with the definition
used in the PROTECT protocol.
If clinicians suspect any VTE event, they will perform
tests as clinically indicated.
Secondary outcomes
1. All incident DVTs including distal DVTs
STUDY PERIOD
Enrolment Allocation Post-allocation Close-out











Baseline Ultrasound X X
Twice Weekly Ultrasound
Mortality X X
Length of Stay X
Duration of Mechanical 
Ventilation X
Fig. 1 Schedule of enrollment, intervention and assessment for the thromboprophylaxis using combined intermittent pneumatic compression
and pharmacologic prophylaxis versus pharmacologic prophylaxis alone in critically ill patients (PREVENT) trial
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2. All DVTs including incident and prevalent DVTs
3. Pulmonary embolism: we will follow the same
definition used in the PROTECT trial. We define PE
as: definite PE (characteristic intraluminal filling
defect on thoracic CT scan, high-probability
ventilation/perfusion (VQ) scan or detected at
autopsy); probable PE (moderate-high pretest
probability (high clinical suspicion) and no test or
a non-diagnostic test); possible PE (low pre-test
probability (low clinical suspicion and a non-diagnostic
test); or no PE (negative or normal test without
reference to pretest probability). PE will be followed up
to ICU discharge or day 28 after randomization
4. Non-lower extremity non-PE thrombotic events
5. All VTE events
6. Skin pressure ulcers using the National Pressure
Ulcer Advisory Panel (NPUAP) classification
7. Lower extremity ischemia
8. Daily level of mobility
9. Vasopressor requirements and vasopressor-free days
(at day 28)
10. Duration of mechanical ventilation and mechanical
ventilation-free days (at day 28)
11. ICU length of stay and ICU-free days (at day 28)
12. Serial cardiovascular and respiratory Sequential
Organ Failure Assessment (SOFA) scores
13. Mortality:
a. ICU mortality: death in the ICU during the same
ICU admission
b. Hospital mortality: death in the hospital (in the
ICU or on the ward) during the same hospital
admission. Hospital mortality will be censored at
1 year from the date of enrollment
c. 28-day mortality: death before or at day 28 of
enrollment
d. 90-day mortality: death before or at day 90 of
enrollment
14. Composite VTE events and 28-day mortality
15. Number of diagnostic tests for VTE including
ultrasounds, spiral CT scans and VQ scans
16. Serious adverse events (Table 3)
Data management
Data are entered through a password-protected access to
an electronic database through an online portal and are
stored on a secure server at King Abdullah International
Medical Research Center, Riyadh, Saudi Arabia. The data-
base includes multiple logic checks for double entry and
range checks for data values. Several procedures to ensure
data quality and protocol standardization are undertaken
including: (1) training sessions for research coordinators
from participating centers prior to study commencement,
(2) a detailed Study Instruction Manual which outlines each
step of the protocol, and (3) startup meetings for all sites,
either by a physical conference or via videoconferencing.
Patient personal data are de-identified. Each site investiga-
tor and coordinator have access to patients’ data from their




Based on our previous observational study [7], the VTE risk
(including DVT and PE) with no IPC was 7.2 % and with
IPC it was 4.8 %. However, in this study no surveillance
ultrasounds were performed. The PROTECT trial [13] doc-
umented a baseline risk for proximal DVT of 5.8 % in pa-
tients receiving unfractionated heparin and 5.1 % in
patients receiving dalteparin. In addition, the PROTECT
trial had a prevalent DVT rate at initial screening of 3.5 %.
In the CLOTS 3 trial, the risk of DVT without IPC was
12.1 % and with IPC 8.5 %. We anticipate a higher baseline
DVT rate than PROTECT because of the wider inclusion
criteria and the inclusion of trauma patients; and lower
than CLOTS 3 in which no pharmacologic prophylaxis was
used routinely. Therefore, we anticipate a baseline risk of
7 % and absolute risk reduction of 3 %. Thus, a sample size
of 1000 subjects in each group (accounting for a 5 % preva-
lent DVT rate and 5 % loss to follow-up) will have 80 %
power to detect an absolute risk reduction of 3 %.
Statistical analysis
We will compare incident proximal lower extremity DVT
between groups using the chi-square test. The unadjusted
Cox proportional hazards model will be used to test the null
hypothesis and will be used as a secondary analysis tool. A
detailed statistical analysis plan will be published separately.
Research governance
The study Steering Committee members will be respon-
sible for overseeing the conduct of the trial, for upholding
Table 3 Deviations, violations and serious adverse events (SAEs)
Conditions/events Actions
Deviation • Follow-up ultrasound not performed
• Follow-up ultrasound
performed late
• Use of GCS for non-
protocolized reasons
• Document in the
CRF/eCRF
• Prepare a note to file
• Notify methods center
Violation • Enrolling a non-eligible patient
• Admission/baseline ultrasound
not done within 48 h of enrollment
• Received wrong intervention
• Prepare a note to file
• Notify site PI
• Notify IRB and
sponsor immediately
• Submit a written




• Skin ulceration categories
III and IV
• Ischemia due to IPC
• Notify site PI
• Notify IRB and sponsor
immediately
CRF case report form, eCRF electronic case report form, IPC intermittent
pneumatic compression, IRB Institutional Review Board, PI physician investigator
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or modifying study procedures as needed, addressing
challenges with protocol implementation, formulating
the analysis plan, reviewing and interpreting the data
and preparing the manuscript. This will be achieved
through meetings (in-person or by conference calls) at
least quarter-yearly. The study Data Safety and Monitor-
ing Board (DSMB) will provide independent input regard-
ing the safety and/or efficacy of the intervention. Upon
completion, the results of the trial are planned to be pub-
lished in a peer-reviewed journal. Authorship will follow
the Uniform Requirements for Manuscripts Submitted to
Biomedical Journals [19].
Discussion
To our knowledge, this is the first RCT that compares
adjunct IPC and pharmacologic prophylaxis versus
pharmacologic prophylaxis alone in critically ill patients.
To enhance the external validity of our findings, patients
will be enrolled from more than 20 hospitals internation-
ally. Central randomization with concealed allocation,
blinded radiologist interpretations and adherence to the
intention-to-treat principle will limit potential sources of
bias. In addition, trial interventions and outcome monitor-
ing will ensure that “loss to follow-up” for the primary
outcome is minimal or absent.
The issue of the safety of critically ill patients is a
prime concern in this randomized trial. Several measures
have been taken to minimize, observe and document
any potential safety concerns (Table 3).
The main limitation to our study is the inability to
blind patients, their caregivers and the ultrasonog-
rapher/technician performing ultrasound with regard to
allocation due to the nature of the intervention. We gave
careful consideration to applying sham IPC in the con-
trol group. After discussion and deliberation, we decided
not to include a sham IPC in the control group due
to the potential harm of placing a cuff on the legs
without inflation.
We used twice-weekly surveillance ultrasound to as-
sess the primary outcome, rather than relying on DVT
clinically suspected by clinicians, because the latter tends
to underestimate the true incidence of DVT. We used a
pragmatic time window of 48 h to perform the first
(baseline ultrasound), and we considered the DVTs iden-
tified on this ultrasound as prevalent DVTs. Because we
are interested in examining whether IPC reduces the in-
cidence of DVT, our primary endpoint is DVTs that
occur in patients who have a normal initial ultrasound
but develop DVT as documented on subsequent exams;
i.e., after the third calendar day (incident DVT).
Our primary endpoint is proximal DVT by surveillance
ultrasound. We will not screen for distal DVTs because of
the debated clinical relevance [20] and because the diag-
nosis by Doppler ultrasound is technically challenging and
results may be inconsistent as reported by the CLOTS 3
trial [8]. However, we will document distal DVT if diag-
nosed by ultrasound obtained by the treating team.
We will also capture data on other outcomes relevant
to IPC use including lower extremity ischemia, pressure
ulcers and mobility. We will follow patients for develop-
ment of safety concerns (lower extremity ischemia and
pressure ulcers) as CLOTS 3 documented lower extrem-
ity skin lesions in 3 % of patients allocated to IPC and in
1 % of those allocated no IPC (p = 0.002) [8]. We will
document the incidence of lower extremity ischemia,
although there is no evidence that IPC causes ischemia.
Additionally, based on clinical concerns that IPC use
may negatively impact mobilization, we will evaluate
whether IPC application reduces the chances of patients
being mobilized.
We followed a pragmatic approach in selecting IPC
devices and sleeve lengths, permitting treating teams at
participating centers to use their own devices (sequential
on non-sequential) and to select the sleeves (knee-length
versus thigh-length) because at present there is no evi-
dence for superiority of any of these choices over others.
The results of this study will contribute to a better un-
derstanding of the effectiveness of IPC in critically ill
adults. In addition, the PREVENT trial will likely con-
tribute to future clinical practice guidelines and patient
safety initiatives by providing evidence that will inform
practice regarding the best thromboprophylaxis for crit-
ically ill adult patients.
Trial status
The first patient was enrolled in July 2014. As of May
2016, a total of 650 patients have been enrolled from 13
centers in Saudi Arabia, Canada and Australia. The first
interim analysis is anticipated in July 2016. We expect to
complete recruitment of 2000 patients by 2018.
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